Arnon Kater
阿农·卡特尔
MD, PhD
Professor of Hematology; Head, CLL Research Program血液学教授兼CLL研究项目负责人
👥Biography 个人简介
Dr. Arnon Kater is a leading European CLL specialist whose work on venetoclax-based combinations has redefined frontline CLL therapy. He was instrumental in the CLL14 trial showing that venetoclax plus obinutuzumab enables deep remissions and MRD-negativity in previously untreated CLL.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Venetoclax Combination Regimens
Co-led the CLL14 trial establishing venetoclax plus obinutuzumab as a fixed-duration frontline CLL standard, demonstrating superior MRD negativity rates over chlorambucil-obinutuzumab and durable PFS benefit.
MRD-Guided CLL Treatment
Pioneered MRD-guided adaptive treatment strategies in CLL, designing trials where therapy duration is adjusted based on measurable residual disease response to optimize outcomes and limit toxicity.
Representative Works 代表性著作
Venetoclax and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL14)
New England Journal of Medicine (2019)
Phase 3 CLL14 trial demonstrating superior PFS with venetoclax-obinutuzumab versus chlorambucil-obinutuzumab in frontline CLL.
MRD-Guided Stop and Go Venetoclax-Based Combination Treatment in Patients with CLL
Journal of Clinical Oncology (2022)
Adaptive MRD-guided approach showing feasibility of treatment cessation in CLL patients achieving deep molecular remission.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 阿农·卡特尔 的研究动态
Follow Arnon Kater's research updates
留下邮箱，当我们发布与 Arnon Kater（Amsterdam UMC）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment